<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32924617</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1-2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis in Antalya, Turkey. A prospective study, 2016-2018.</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>107</EndPage><MedlinePgn>101-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1817089</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The aim of the study is to find the prevalence and incidence of amyotrophic lateral sclerosis in Antalya and to define patient characteristics.</AbstractText><AbstractText Label="METHODS">The study represents five major districts in the Antalya metropolitan region, with a population of 1,286,943, which is defined as the provincial center. In cooperation with the neurology departments of all hospitals and private practices, existing cases were identified and new cases were recorded with continuous monitoring. Detailed demographic and clinical features of each patient were recorded, Revised El-Escorial Criteria were used for diagnosis. Incidence and prevalence rates are standardized by age based on USA 2016 population.</AbstractText><AbstractText Label="RESULTS">Point prevalence rates of 2016, 2017 and 2018 are 3.7, 4.7 and 5.4 per hundred thousand, respectively. Standardized prevalence rates for the US population are 5.5, 7.1 and 8.6 per hundred thousand in the same order. The incidence rate in 2017 is 1.4 per hundred thousand, and 2018 is 1.2. Standardized incidence rates for the US population are 2.1 and 1.8 per hundred thousand, respectively. About 75.6% of the cases were classified as definite, 11.0% probable, 11.0% possible, 2.4% probable laboratory-supported. The male/female ratio is 2.0 for total cases and 2.8 for new cases. The site of onset is spinal in 81.7% of patients and bulbar in 18.3%.</AbstractText><AbstractText Label="CONCLUSIONS">ALS rates detected in Antalya and the general features of the disease show similarities with European countries rather than Asian countries and comply with the literature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uysal</LastName><ForeName>Hilmi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6063-377X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taghiyeva</LastName><ForeName>Parvin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xfc;rkay</LastName><ForeName>Mehtap</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health, Faculty of Medicine, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;se</LastName><ForeName>F&#x131;rat</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Public Health, Faculty of Medicine, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aktekin</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0745-9194</Identifier><AffiliationInfo><Affiliation>Department of Public Health, Faculty of Medicine, Akdeniz University, Antalya, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Antalya</Keyword><Keyword MajorTopicYN="N">Turkey</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">period prevalence</Keyword><Keyword MajorTopicYN="N">point prevalence</Keyword><Keyword MajorTopicYN="N">prospective study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32924617</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1817089</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>